Faeth Therapeutics, Inc. Stock-Based Compensation
Faeth Therapeutics, Inc. (FTH) reported Stock-Based Compensation of $17.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $4.48M, a 1598.11% increase year-over-year.
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $12.90M, a 2697.83% increase year-over-year.
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $295.00K, a 24.55% decline year-over-year.
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $254.00K, a 65.35% decline year-over-year.
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.27M, a 59.36% decline from fiscal 2024.
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $3.13M, a 29.61% decline from fiscal 2023.
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $4.45M, a 23.37% decline from fiscal 2022.
- Faeth Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $5.81M, a 2.74% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $17.38M 10-Q · filed 2026-08-04 | $17.68M derived: sum of 3 quarters · filed 2026-08-04 | $17.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $12.90M 10-Q · filed 2026-05-15 | $13.19M derived: sum of 2 quarters · filed 2026-05-15 | $13.45M derived: sum of 3 quarters · filed 2026-05-15 | $13.71M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $549.00K derived: sum of 2 quarters · filed 2026-03-30 | $813.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.27M 10-K · filed 2026-03-30 |
| 2025-09-30 | $254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $518.00K derived: sum of 2 quarters · filed 2026-08-04 | $979.00K 10-Q · filed 2025-11-14 | $1.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $264.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $725.00K 10-Q · filed 2026-08-04 | $1.12M derived: sum of 3 quarters · filed 2026-08-04 | $1.85M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $461.00K 10-Q · filed 2026-05-15 | $852.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.58M derived: sum of 3 quarters · filed 2026-05-15 | $2.38M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $391.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.12M derived: sum of 2 quarters · filed 2026-03-30 | $1.92M derived: sum of 3 quarters · filed 2026-03-30 | $3.13M 10-K · filed 2026-03-30 |
| 2024-09-30 | $733.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.53M derived: sum of 2 quarters · filed 2025-11-14 | $2.74M 10-Q · filed 2025-11-14 | $3.84M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $795.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.01M 10-Q · filed 2025-08-05 | $3.11M derived: sum of 3 quarters · filed 2025-08-05 | $4.16M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.22M 10-Q · filed 2025-05-06 | $2.31M derived: sum of 2 quarters · filed 2025-05-06 | $3.36M derived: sum of 3 quarters · filed 2025-05-06 | $4.46M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.15M derived: sum of 2 quarters · filed 2025-03-28 | $3.24M derived: sum of 3 quarters · filed 2025-03-28 | $4.45M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.14M derived: sum of 2 quarters · filed 2024-11-14 | $3.36M 10-Q · filed 2024-11-14 | $4.75M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.31M 10-Q · filed 2024-08-06 | $3.71M derived: sum of 3 quarters · filed 2024-08-06 | $5.19M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.21M 10-Q · filed 2024-05-09 | $2.61M derived: sum of 2 quarters · filed 2024-05-09 | $4.09M derived: sum of 3 quarters · filed 2024-05-09 | $5.51M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.88M derived: sum of 2 quarters · filed 2024-02-29 | $4.30M derived: sum of 3 quarters · filed 2024-02-29 | $5.81M 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.90M derived: sum of 2 quarters · filed 2023-11-07 | $4.41M 10-Q · filed 2023-11-07 | $5.24M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.93M 10-Q · filed 2023-08-03 | $3.76M derived: sum of 3 quarters · filed 2023-08-03 | $5.50M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.51M 10-Q · filed 2023-05-09 | $2.34M derived: sum of 2 quarters · filed 2023-05-09 | $4.08M derived: sum of 3 quarters · filed 2023-05-09 | $5.82M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $2.56M derived: sum of 2 quarters · filed 2023-03-29 | $4.31M derived: sum of 3 quarters · filed 2023-03-29 | $5.66M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.48M derived: sum of 2 quarters · filed 2022-11-08 | $4.83M 10-Q · filed 2022-11-08 | $5.18M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.10M 10-Q · filed 2022-08-09 | $3.45M derived: sum of 3 quarters · filed 2022-08-09 | $4.23M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.35M 10-Q · filed 2022-05-10 | $1.70M derived: sum of 2 quarters · filed 2022-05-10 | $2.48M derived: sum of 3 quarters · filed 2022-05-10 | $2.65M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.14M derived: sum of 2 quarters · filed 2022-03-15 | $1.30M derived: sum of 3 quarters · filed 2022-03-15 | $1.49M 10-K · filed 2022-03-15 |
| 2020-09-30 | $781.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $944.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.14M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $357.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $194.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |